Imexpharm Statistics

Total Valuation

Imexpharm has a market cap or net worth of VND 7.47 trillion. The enterprise value is 7.25 trillion.

Market Cap	7.47T
Enterprise Value	7.25T

Important Dates

The next estimated earnings date is Friday, April 18, 2025.

Earnings Date	Apr 18, 2025
Ex-Dividend Date	Jul 11, 2024

Share Statistics

Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -0.00% in one year.

Current Share Class	n/a
Shares Outstanding	154.01M
Shares Change (YoY)	-0.00%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.64%
Float	n/a

Valuation Ratios

The trailing PE ratio is 25.10 and the forward PE ratio is 20.05.

PE Ratio	25.10
Forward PE	20.05
PS Ratio	3.39
PB Ratio	3.42
P/TBV Ratio	3.54
P/FCF Ratio	62.51
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.96, with an EV/FCF ratio of 60.68.

EV / Earnings	24.37
EV / Sales	3.29
EV / EBITDA	13.96
EV / EBIT	17.47
EV / FCF	60.68

Financial Position

The company has a current ratio of 4.38, with a Debt / Equity ratio of 0.04.

Current Ratio	4.38
Quick Ratio	2.03
Debt / Equity	0.04
Debt / EBITDA	0.17
Debt / FCF	0.72
Interest Coverage	118.98

Financial Efficiency

Return on equity (ROE) is 15.04% and return on invested capital (ROIC) is 11.79%.

Return on Equity (ROE)	15.04%
Return on Assets (ROA)	10.60%
Return on Invested Capital (ROIC)	11.79%
Return on Capital Employed (ROCE)	19.02%
Revenue Per Employee	1.52B
Profits Per Employee	204.91M
Employee Count	1,452
Asset Turnover	0.90
Inventory Turnover	1.68

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +64.92% in the last 52 weeks. The beta is 0.94, so Imexpharm's price volatility has been similar to the market average.

Beta (5Y)	0.94
52-Week Price Change	+64.92%
50-Day Moving Average	46,557.00
200-Day Moving Average	42,352.46
Relative Strength Index (RSI)	58.88
Average Volume (20 Days)	229,210

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imexpharm had revenue of VND 2.21 trillion and earned 297.54 billion in profits. Earnings per share was 1,931.94.

Revenue	2.21T
Gross Profit	1.03T
Operating Income	415.16B
Pretax Income	404.19B
Net Income	297.54B
EBITDA	519.39B
EBIT	415.16B
Earnings Per Share (EPS)	1,931.94

Full Income Statement

Balance Sheet

The company has 303.98 billion in cash and 86.12 billion in debt, giving a net cash position of 217.86 billion or 1,414.60 per share.

Cash & Cash Equivalents	303.98B
Total Debt	86.12B
Net Cash	217.86B
Net Cash Per Share	1,414.60
Equity (Book Value)	2.18T
Book Value Per Share	14,175.27
Working Capital	1.09T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 214.15 billion and capital expenditures -94.65 billion, giving a free cash flow of 119.50 billion.

Operating Cash Flow	214.15B
Capital Expenditures	-94.65B
Free Cash Flow	119.50B
FCF Per Share	775.91

Full Cash Flow Statement

Margins

Gross margin is 46.52%, with operating and profit margins of 18.83% and 14.55%.

Gross Margin	46.52%
Operating Margin	18.83%
Pretax Margin	18.33%
Profit Margin	14.55%
EBITDA Margin	23.55%
EBIT Margin	18.83%
FCF Margin	5.42%

Dividends & Yields

This stock pays an annual dividend of 454.55, which amounts to a dividend yield of 0.94%.

Dividend Per Share	454.55
Dividend Yield	0.94%
Dividend Growth (YoY)	10.00%
Years of Dividend Growth	1
Payout Ratio	21.82%
Buyback Yield	0.00%
Shareholder Yield	0.94%
Earnings Yield	3.98%
FCF Yield	1.60%

Dividend Details

Stock Splits

The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.

Last Split Date	Sep 17, 2024
Split Type	Forward
Split Ratio	2

Scores

Imexpharm has an Altman Z-Score of 13.04.

Altman Z-Score	13.04
Piotroski F-Score	n/a